Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Dyne Therapeutics ( (DYN) ) just unveiled an update.
On June 27, 2025, Dyne Therapeutics entered into a Loan and Security Agreement with Hercules Capital and other lenders for term loans up to $275 million. This agreement, which includes multiple tranches and a maturity date of July 1, 2030, provides Dyne with financial flexibility to support its clinical, regulatory, and commercial milestones. The loan is secured by a first-priority interest in Dyne’s assets and includes covenants related to cash maintenance and revenue targets, reflecting the company’s strategic focus on advancing its therapeutic pipeline.
The most recent analyst rating on (DYN) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Dyne Therapeutics stock, see the DYN Stock Forecast page.
Spark’s Take on DYN Stock
According to Spark, TipRanks’ AI Analyst, DYN is a Neutral.
Dyne Therapeutics’ stock score reflects its current financial health as a pre-revenue biotech, burdened by losses but supported by a strong balance sheet and recent strategic leadership changes. Technical indicators suggest bearish trends, yet the potential for future breakthroughs could alter its trajectory.
To see Spark’s full report on DYN stock, click here.
More about Dyne Therapeutics
Dyne Therapeutics, Inc. operates in the biotechnology industry, focusing on developing targeted therapies for patients with serious muscle diseases. The company is known for its innovative approaches in addressing unmet medical needs through its proprietary technologies.
Average Trading Volume: 2,775,806
Technical Sentiment Signal: Sell
Current Market Cap: $1.09B
For an in-depth examination of DYN stock, go to TipRanks’ Overview page.